Owens D R, Jones M K, Hayes T M, Heding L G, Alberti K G, Home P D, Burrin J M, Newcombe R G
Br Med J (Clin Res Ed). 1981 Apr 18;282(6272):1264-6. doi: 10.1136/bmj.282.6272.1264.
The safety and efficacy of a new highly purified neutral soluble human insulin produced by conversion of porcine insulin was compared with a highly purified neutral soluble porcine insulin in six normal men. The insulins were administered by subcutaneous injection at a dose of 0.075 U/kg body weight. Somatostatin was infused during the experiment to suppress endogenous insulin secretin. No difference was found in the plasma glucose, insulin, or metabolite responses. Thus the potency, onset, and duration of effect were identical with the two insulins. No short-term side effects to either insulin were observed. Highly purified, semi-synthetic human insulin offers a safe and effective means to explore the possible advantages of homologous human insulin in the management of diabetes mellitus.
在六名正常男性中，将通过猪胰岛素转化生产的新型高纯度中性可溶性人胰岛素与高纯度中性可溶性猪胰岛素的安全性和有效性进行了比较。胰岛素通过皮下注射给药，剂量为0.075 U/kg体重。实验期间输注生长抑素以抑制内源性胰岛素分泌。在血浆葡萄糖、胰岛素或代谢物反应方面未发现差异。因此，两种胰岛素的效力、起效时间和作用持续时间相同。未观察到两种胰岛素有短期副作用。高纯度半合成人胰岛素为探索同源人胰岛素在糖尿病管理中可能的优势提供了一种安全有效的手段。
